These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31512295)

  • 1. Circulating unconventional T-cell subsets during treatment with BCR-ABL1 tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia.
    Konuma T; Kohara C; Watanabe E; Mizukami M; Nagai E; Kato S; Takahashi S; Tojo A
    Eur J Haematol; 2019 Dec; 103(6):623-625. PubMed ID: 31512295
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 3. The story of tyrosine kinase inhibitors discontinuation in clinical practice.
    Rousselot P
    Leuk Lymphoma; 2018 Dec; 59(12):2782-2791. PubMed ID: 29909726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
    Baccarani M; Soverini S; De Benedittis C
    Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.
    Rabian F; Lengline E; Rea D
    Curr Hematol Malig Rep; 2019 Dec; 14(6):492-500. PubMed ID: 31760572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
    Valent P
    Lancet Oncol; 2010 Nov; 11(11):1010-1. PubMed ID: 20965784
    [No Abstract]   [Full Text] [Related]  

  • 9. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.
    Zhang J; Wang Y; Wang J; Hu J; Chen S; Jin J; Liu T; Zhou J; Hu Y; Ma D; Huang X; Ji C; Hou M
    Blood Cancer J; 2018 Jun; 8(7):61. PubMed ID: 29915172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
    Arora R; Press RD
    Leuk Lymphoma; 2017 Jan; 58(1):8-16. PubMed ID: 27412040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.
    Stella S; Tirró E; Massimino M; Vitale SR; Russo S; Pennisi MS; Puma A; Romano C; DI Gregorio S; Innao V; Stagno F; DI Raimondo F; Musolino C; Manzella L
    In Vivo; 2019; 33(5):1593-1598. PubMed ID: 31471409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
    Kantarjian H; Cortes J
    J Clin Oncol; 2011 Apr; 29(12):1512-6. PubMed ID: 21422414
    [No Abstract]   [Full Text] [Related]  

  • 14. Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome.
    Chakraborty R; Mukkamalla SK; Singam K; Calderon N
    Korean J Intern Med; 2014 Nov; 29(6):827-9. PubMed ID: 25378984
    [No Abstract]   [Full Text] [Related]  

  • 15. BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.
    Leonetti F; Stefanachi A; Nicolotti O; Catto M; Pisani L; Cellamare S; Carotti A
    Curr Med Chem; 2011; 18(19):2943-59. PubMed ID: 21651486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
    Mahon FX
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):101-103. PubMed ID: 30845112
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization.
    Cross NC; Hochhaus A; Müller MC
    Ann Hematol; 2015 Apr; 94 Suppl 2():S219-25. PubMed ID: 25814088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.
    Gustafson D; Fish JE; Lipton JH; Aghel N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):20-30. PubMed ID: 32078113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia.
    Engel NW; Constantin A; Fowlkes S; Assouline S
    J Oncol Pract; 2016 Jun; 12(6):592-4. PubMed ID: 27246687
    [No Abstract]   [Full Text] [Related]  

  • 20. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.